Your English writing platform
Discover LudwigSuggestions(1)
Exact(6)
A total of 70 patients in our cohort had a first progression of their disease after autologous transplantation, with 27 patients progressing in the super mobiliser and 43 patients in the normal mobiliser group.
The resistant group was defined as presenting a first progression during or within 6 months following the end of treatment.
A first progression period (XIXth and beginning of XXth century) was modeled for the older events (Oxford-Cambridge, Vasaloppet, speed ski record, ICU cycling: r2 = 0.97±0.03, a = 1.93±0.96 and β' = 57.6±8.9%; Figure 1).
In the present study, only 2 (3.8%) patients had a CNS lesion as a first progression event.
And, CNS was a first progression site in five (10.2%) patients among 49 patients in the OED group.
For example, Burstein et al. demonstrated that approximately 10%% of patients receiving first-line trastuzumab-based regimens had isolated CNS recurrence as a first progression event.
Similar(54)
There is a second progression to observe: the exile's return.
A second progression period starts in the early XXth century for seven events (the four previous ones plus Channel crossing, Elfstedentocht (Figure 2) and IHPVA cycling: r2 = 0.95±0.03, a = 0.97±0.45, β' = 73.15±16.8%).
We show that 64% of T&F events no longer improved since 1993, while 47% of swimming events stagnated after 1990, prior to a second progression step starting in 2000.
After dose-escalation, 8 out of 10 patients had a second progression after transient stabilisation of their disease for a median of 12 months (range 2 30).
4 In patients with KRAS-wild-type tumors, regorafenib may be used following a second progression on FOLFOX or FOLFIRI, as long as bevacizumab and cetuximab were used in either first- or second-line.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com